

Alfredo Carrato

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1316796/alfredo-carrato-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

341 papers	12,245 citations	55 h-index	101 g-index
392 ext. papers	14,099 ext. citations	5.3 avg, IF	5.44 L-index

#	Paper	IF	Citations
341	Capecitabine as adjuvant treatment for stage III colon cancer. <i>New England Journal of Medicine</i> , 2005 , 352, 2696-704	59.2	958
340	NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. <i>Lancet, The</i> , 2005 , 366, 649-59	40	483
339	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. <i>Nature Genetics</i> , 2010 , 42, 978-84	36.3	408
338	Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 12-8	2.2	390
337	Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools. <i>American Journal of Epidemiology</i> , 2007 , 165, 148-56	3.8	382
336	Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3664-71	2.2	256
335	Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1884-89	2.2	219
334	Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. <i>European Journal of Cancer</i> , 2007 , 43, 2037-45	7.5	203
333	Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. <i>Lancet Oncology, The</i> , 2008 , 9, 359-66	21.7	193
332	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2010-9	2.2	192
331	Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. <i>Nature Genetics</i> , 2013 , 45, 1464-9	36.3	186
330	Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. <i>Clinical and Translational Oncology</i> , 2005 , 7, 189-97	3.6	179
329	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017 , 35, 446-464	2.2	176
328	PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. <i>Cancer Research</i> , 2006 , 66, 7401-4	10.1	175
327	Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. <i>European Urology</i> , 2014 , 65, 360-6	10.2	166
326	Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. <i>Clinical Cancer Research</i> , 2007 , 13, 3545-51	12.9	164
325	Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain. <i>Environmental Health Perspectives</i> , 2010 , 118, 1545-50	8.4	162

324	Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3207-13	2.2	159
323	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. <i>Gut</i> , 2020 , 69, 7-17	19.2	159
322	Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. <i>Lancet, The</i> , 1999 , 354, 2125-9	40	146
321	A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. <i>Journal of Gastrointestinal Cancer</i> , 2015 , 46, 201-11	1.6	143
320	Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. <i>Annals of Oncology</i> , 2003 , 14, 833-42	10.3	130
319	Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 536-42	4	128
318	Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1348-54	4	121
317	Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. <i>BMC Cancer</i> , 2015 , 15, 797	4.8	116
316	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. <i>Annals of Oncology</i> , 2015 , 26, 921-927	10.3	110
315	Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1341-7	2.2	110
314	Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. <i>PLoS Genetics</i> , 2007 , 3, e29	6	109
313	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv279	9.7	107
312	Genetic variation in the base excision repair pathway and bladder cancer risk. <i>Human Genetics</i> , 2007 , 121, 233-42	6.3	107
311	Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. <i>Annals of Oncology</i> , 2006 , 17, 467-72	10.3	106
310	FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. <i>Clinical Cancer Research</i> , 2005 , 11, 5444-50	12.9	106
309	Genome-wide association study identifies multiple loci associated with bladder cancer risk. <i>Human Molecular Genetics</i> , 2014 , 23, 1387-98	5.6	101
308	Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. <i>American Journal of Human Genetics</i> , 2010 , 87, 129-38	11	100
307	Food, nutrient and heterocyclic amine intake and the risk of bladder cancer. <i>European Journal of Cancer</i> , 2007 , 43, 1731-40	7.5	99

306	Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. <i>Gut</i> , 2019 , 68, 130-139	19.2	86
305	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). <i>Annals of Oncology</i> , 2015 , 26, 1987-1993 ^{10.3}		85
304	Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3545-51	2.2	85
303	Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. <i>Anti-Cancer Drugs</i> , 2010 , 21 Suppl 1, S3-11	2.4	83
302	Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. <i>Carcinogenesis</i> , 2007 , 28, 1788-93	4.6	83
301	Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. <i>Cancer Research</i> , 2013 , 73, 2211-20	10.1	82
300	A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. <i>Human Molecular Genetics</i> , 2011 , 20, 4282-9 ^{5.6}		82
299	An unusual suspect: an uncommon human-specific synonymous coding variant within the UGT1A6 gene explains a GWAS signal and protects against bladder cancer. <i>Genome Biology</i> , 2011 , 12,	18.3	78
298	Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. <i>Annals of Oncology</i> , 1998 , 9, 727-31	10.3	78
297	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014 , 23, 6616-33	5.6	77
296	Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. <i>Carcinogenesis</i> , 2008 , 29, 1955-62	4.6	76
295	UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. <i>British Journal of Cancer</i> , 2010 , 103, 581-9	8.7	72
294	Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 1595-600	4	70
293	Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 4974-9	11.5	69
292	Pancreatic cancer risk and levels of trace elements. <i>Gut</i> , 2012 , 61, 1583-8	19.2	68
291	Genetic and non-genetic predictors of LINE-1 methylation in leukocyte DNA. <i>Environmental Health Perspectives</i> , 2013 , 121, 650-6	8.4	66
290	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 1345-1363	5	64
289	Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. <i>European Journal of Cancer</i> , 2013 , 49, 2416-24	7.5	63

288	The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. <i>BMC Genomics</i> , 2015 , 16, 403	4.5	59
287	Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. <i>Human Molecular Genetics</i> , 2012 , 21, 1918-30	5.6	58
286	Refinement of screening for familial pancreatic cancer. <i>Gut</i> , 2016 , 65, 1314-21	19.2	54
285	Total fluid and water consumption and the joint effect of exposure to disinfection by-products on risk of bladder cancer. <i>Environmental Health Perspectives</i> , 2007 , 115, 1569-72	8.4	53
284	Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. <i>International Journal of Cancer</i> , 2007 , 120, 2452-8	7.5	53
283	The p53 pathway and outcome among patients with T1G3 bladder tumors. <i>Clinical Cancer Research</i> , 2006 , 12, 6029-36	12.9	53
282	First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). <i>European Journal of Cancer</i> , 2017 , 81, 191-202	7.5	52
281	First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 77, 78-84	7	52
280	Genetic susceptibility to distinct bladder cancer subphenotypes. <i>European Urology</i> , 2010 , 57, 283-92	10.2	52
279	Air pollution and risk of urinary bladder cancer in a case-control study in Spain. <i>Occupational and Environmental Medicine</i> , 2008 , 65, 56-60	2.1	51
278	Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1222-30	6.1	50
277	Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. <i>Journal of Epidemiology and Community Health</i> , 1999 , 53, 702-9	5.1	50
276	Integration Analysis of Three Omics Data Using Penalized Regression Methods: An Application to Bladder Cancer. <i>PLoS Genetics</i> , 2015 , 11, e1005689	6	49
275	Occupation and bladder cancer in a hospital-based case-control study in Spain. <i>Occupational and Environmental Medicine</i> , 2008 , 65, 347-53	2.1	48
274	Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level. <i>Cancer Letters</i> , 2010 , 290, 192-203	9.9	47
273	Assessment of lifetime exposure to trihalomethanes through different routes. <i>Occupational and Environmental Medicine</i> , 2006 , 63, 273-7	2.1	47
272	Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer. <i>International Journal of Cancer</i> , 2003 , 107, 635-41	7.5	47
271	Differential distribution and enrichment of non-coding RNAs in exosomes from normal and Cancer-associated fibroblasts in colorectal cancer. <i>Molecular Cancer</i> , 2018 , 17, 114	42.1	45

270	Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1071-7	2.2	45
269	Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 70, 134-44	7	42
268	Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain. <i>European Journal of Cancer</i> , 2006 , 42, 1448-54	7.5	42
267	Oxaliplatin: results in colorectal carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 44, 29-44	7	42
266	Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. <i>European Urology</i> , 2003 , 43, 53-62	10.2	42
265	TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. <i>International Journal of Cancer</i> , 2009 , 124, 608-13	7.5	41
264	Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1696-702	4	41
263	Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. <i>Carcinogenesis</i> , 2002 , 23, 101-6	4.6	40
262	Reduced risk of pancreatic cancer associated with asthma and nasal allergies. <i>Gut</i> , 2017 , 66, 314-322	19.2	37
261	Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. <i>Cancer and Metastasis Reviews</i> , 2011 , 30 Suppl 1, 19-26	9.6	35
260	A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2015 , 26, 2085-91	10.3	34
259	Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). <i>European Journal of Cancer</i> , 2008 , 44, 2204-11	7.5	34
258	Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. <i>Molecular Cancer Research</i> , 2007 , 5, 641-53	6.6	34
257	Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background. <i>PLoS ONE</i> , 2012 , 7, e29396	3.7	33
256	PanGen-Fam: Spanish registry of hereditary pancreatic cancer. <i>European Journal of Cancer</i> , 2015 , 51, 1911-7	7.5	32
255	Coffee consumption, genetic susceptibility and bladder cancer risk. <i>Cancer Causes and Control</i> , 2009 , 20, 121-7	2.8	32
254	Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer. <i>Lung Cancer</i> , 2000 , 28, 97-107	5.9	32
253	Tumor-associated macrophage-secreted 14-3-3 signals via AXL to promote pancreatic cancer chemoresistance. <i>Oncogene</i> , 2019 , 38, 5469-5485	9.2	31

252	Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. <i>International Journal of Epidemiology</i> , 2007 , 36, 236-41	7.8	31
251	Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. PANKRAS II Study Group. <i>European Journal of Epidemiology</i> , 2000 , 16, 533-41	12.1	31
250	Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 1430-6	4	30
249	Occupation and pancreatic cancer in Spain: a case-control study based on job titles. PANKRAS II Study Group. <i>International Journal of Epidemiology</i> , 2000 , 29, 1004-13	7.8	30
248	Adjuvant treatment of colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, S42-6		30
247	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. <i>American Journal of Clinical Pathology</i> , 2016 , 146, 647-669	1.9	30
246	Biomarkers for early diagnosis of pancreatic cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 305-15	4.2	29
245	Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. <i>Current Medical Research and Opinion</i> , 2014 , 30, 447-61	2.5	29
244	What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 83-106	7	29
243	Urinary pH, cigarette smoking and bladder cancer risk. <i>Carcinogenesis</i> , 2011 , 32, 843-7	4.6	28
242	Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1897-904	9.7	28
241	A polymeric chip for micromanipulation and particle sorting by ultrasounds based on a multilayer configuration. <i>Sensors and Actuators B: Chemical</i> , 2010 , 144, 310-317	8.5	28
240	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys". <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	27
239	Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. <i>European Journal of Cancer Care</i> , 2010 , 19, 648-55	2.4	26
238	Adjuvant chemotherapy for stages II, III and IV of colon cancer. <i>Clinical and Translational Oncology</i> , 2009 , 11, 526-33	3.6	26
237	ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. <i>Nature Communications</i> , 2020 , 11, 2682	17.4	25
236	F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 1432-1441	12.9	25
235	Does increased urination frequency protect against bladder cancer?. <i>International Journal of Cancer</i> , 2008 , 123, 1644-8	7.5	25

234	Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2004 , 6, 175-83	4.9	25
233	Occupational exposures and risk of pancreatic cancer. <i>European Journal of Epidemiology</i> , 2010 , 25, 721-30	2.1	24
232	Adjuvant therapy of resected gastric cancer is necessary. <i>Seminars in Oncology</i> , 2005 , 32, S105-8	5.5	24
231	Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	23
230	Medical conditions in patients with pancreatic and biliary diseases: validity and agreement between data from questionnaires and medical records. PANKRAS II Study Group. <i>Digestive Diseases and Sciences</i> , 1999 , 44, 2469-77	4	23
229	Food and nutrient intakes and K-ras mutations in exocrine pancreatic cancer. <i>Journal of Epidemiology and Community Health</i> , 2007 , 61, 641-9	5.1	22
228	Lifetime history of tobacco consumption and K-ras mutations in exocrine pancreatic cancer. <i>Pancreas</i> , 2007 , 35, 135-41	2.6	22
227	Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. <i>Molecular Diagnosis and Therapy</i> , 2015 , 19, 397-408	4.5	21
226	LINE-1 methylation in granulocyte DNA and trihalomethane exposure is associated with bladder cancer risk. <i>Epigenetics</i> , 2014 , 9, 1532-9	5.7	21
225	Treatment recommendations for metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 162-78	3.6	21
224	Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. <i>Clinical and Translational Oncology</i> , 2010 , 12, 142-7	3.6	21
223	A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). <i>Cancer</i> , 1995 , 76, 559-63	6.4	21
222	First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. <i>ESMO Open</i> , 2020 , 5,	6	20
221	Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. <i>International Journal of Epidemiology</i> , 2018 , 47, 473-483	7.8	20
220	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016 , 25, 1203-14	5.6	20
219	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. <i>Annals of Oncology</i> , 2012 , 23, 119-127	10.3	20
218	The 18q21 region in colorectal and pancreatic cancer: independent loss of DCC and DPC4 expression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000 , 1502, 283-96	6.9	20
217	Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis. <i>PLoS ONE</i> , 2012 , 7, e45025	3.7	20

216	Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. <i>Oncotarget</i> , 2018 , 9, 32984-32996	3.3	20
215	The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. <i>Cancer Research</i> , 2014 , 74, 5808-18	10.1	19
214	Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2005 , 16, 597-601	10.3	19
213	Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , 2017 , 19, 667-681	3.6	18
212	Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs. <i>Cancers</i> , 2019 , 11,	6.6	18
211	Seom guidelines for the treatment of gastric cancer 2015. <i>Clinical and Translational Oncology</i> , 2015 , 17, 996-1004	3.6	18
210	Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: the Spanish bladder cancer study. <i>International Journal of Cancer</i> , 2013 , 133, 597-603	7.5	18
209	Incomplete overlapping of biological, clinical, and environmental information in molecular epidemiological studies: a variety of causes and a cascade of consequences. <i>Journal of Epidemiology and Community Health</i> , 2002 , 56, 734-8	5.1	17
208	Coffee, pancreatic cancer, and K-ras mutations: updating the research agenda. <i>Journal of Epidemiology and Community Health</i> , 2000 , 54, 656-9	5.1	17
207	ROLE OF PARENTERAL NUTRITION IN ONCOLOGIC PATIENTS WITH INTESTINAL OCCLUSION AND PERITONEAL CARCINOMATOSIS. <i>Nutricion Hospitalaria</i> , 2015 , 32, 1222-7	1	17
206	Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. <i>Cancer Treatment Reviews</i> , 2016 , 50, 142-147	14.4	17
205	Supportive care in pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017 , 19, 1293-1302	13.02	16
204	Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. <i>Gut</i> , 2021 , 70, 319-329	19.2	16
203	A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. <i>EBioMedicine</i> , 2020 , 53, 102675	8.8	16
202	LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk. <i>British Journal of Cancer</i> , 2014 , 110, 2123-30	8.7	16
201	Biological and statistical approaches for modeling exposure to specific trihalomethanes and bladder cancer risk. <i>American Journal of Epidemiology</i> , 2013 , 178, 652-60	3.8	16
200	Socioeconomic status and exposure to disinfection by-products in drinking water in Spain. <i>Environmental Health</i> , 2011 , 10, 18	6	16
199	A significant response to sunitinib in a patient with anaplastic thyroid carcinoma. <i>Journal of Research in Medical Sciences</i> , 2013 , 18, 623-5	1.6	16

198	A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. <i>Annals of Oncology</i> , 2017 , 28, 1618-1624	10.3	15
197	Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1009-1018	4	15
196	Utility of p16 immunohistochemistry for the identification of Lynch syndrome. <i>Clinical Cancer Research</i> , 2009 , 15, 3156-62	12.9	15
195	Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. <i>Lung Cancer</i> , 1997 , 17, 261-9	5.9	15
194	Hodgkin's disease after treatment of non-Hodgkin's lymphoma. <i>Cancer</i> , 1987 , 60, 887-96	6.4	15
193	Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. <i>Annals of Oncology</i> , 2019 , 30, 439-446	10.3	14
192	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. <i>European Journal of Internal Medicine</i> , 2019 , 66, 1-8	3.9	14
191	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). <i>Journal of Gastrointestinal Cancer</i> , 2015 , 46, 109-17	1.6	14
190	From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. <i>Journal of Cancer</i> , 2018 , 9, 1978-1988	4.5	14
189	Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 200-6	3.8	14
188	The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study. <i>BMC Cancer</i> , 2009 , 9, 193	4.8	14
187	Micronuclei assessment in the urothelial cells of women using hair dyes and its modulation by genetic polymorphisms. <i>Cancer Letters</i> , 2008 , 263, 259-66	9.9	14
186	Work in the textile industry in Spain and bladder cancer. <i>Occupational and Environmental Medicine</i> , 2008 , 65, 552-9	2.1	14
185	Detection of terminal deoxynucleotidyl transferase (TdT) by flow cytometry in leukemic disorders. <i>Journal of Histochemistry and Cytochemistry</i> , 1989 , 37, 509-13	3.4	14
184	Mild pancreatic damage in acute viral hepatitis. <i>Digestion</i> , 1989 , 42, 93-7	3.6	14
183	Ambient air pollution and incident bladder cancer risk: Updated analysis of the Spanish Bladder Cancer Study. <i>International Journal of Cancer</i> , 2019 , 145, 894-900	7.5	14
182	Risk of pancreatic cancer and occupational exposures in Spain. PANKRAS II Study Group. <i>Annals of Occupational Hygiene</i> , 2000 , 44, 391-403		14
181	Unusual focal keratin expression in plexiform angiomyxoid myofibroblastic tumor: A case report and review of the literature. <i>Medicine (United States)</i> , 2016 , 95, e4207	1.8	13

180	Genetic variation in the TP53 pathway and bladder cancer risk. a comprehensive analysis. <i>PLoS ONE</i> , 2014 , 9, e89952	3.7	13
179	Bladder cancer and reproductive factors among women in Spain. <i>Cancer Causes and Control</i> , 2009 , 20, 1907-13	2.8	13
178	Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). <i>Annals of Oncology</i> , 1996 , 7, 581-5	10.3	13
177	Anti-VEGF therapy: a new approach to colorectal cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 1385-96	3.5	13
176	Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR. <i>Histopathology</i> , 2005 , 46, 389-95	7.3	13
175	Endothelial cell activation on 3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1. <i>Oncogenesis</i> , 2018 , 7, 76	6.6	13
174	A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study. <i>European Journal of Cancer</i> , 2013 , 49, 1868-75	7.5	12
173	Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk. <i>PLoS ONE</i> , 2013 , 8, e83745	3.7	12
172	Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. <i>European Journal of Epidemiology</i> , 2011 , 26, 229-36	12.1	12
171	Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. <i>Annals of Oncology</i> , 2009 , 20, 251-7	10.3	12
170	The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study. <i>BMC Cancer</i> , 2009 , 9, 406	4.8	12
169	Biallelic MYH germline mutations as cause of Muir-Torre syndrome. <i>Familial Cancer</i> , 2010 , 9, 151-4	3	12
168	Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. <i>Lung Cancer</i> , 2003 , 39, 201-7	5.9	12
167	A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1992 , 15, 56-60	2.7	12
166	Detection of intracytoplasmic immunoglobulin by flow cytometry in B-cell malignancies. <i>Journal of Histochemistry and Cytochemistry</i> , 1989 , 37, 83-9	3.4	12
165	Tyrosine Kinase Receptors in Oncology. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	12
164	A Label Free Disposable Device for Rapid Isolation of Rare Tumor Cells from Blood by Ultrasounds. <i>Micromachines</i> , 2018 , 9,	3.3	12
163	A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e323-e329	3.8	11

162	Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level. <i>Clinical and Translational Oncology</i> , 2011 , 13, 341-7	3.6	11
161	Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. <i>Acta Oncologica</i> , 2008 , 47, 286-92	3.2	11
160	Etoposide (E) + epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Therapy (T.T.D.). <i>Annals of Oncology</i> , 1992 , 3, 861-3	10.3	11
159	Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. <i>Annals of Oncology</i> , 2018 , 29, 439-444	10.3	10
158	Whole genome prediction of bladder cancer risk with the Bayesian LASSO. <i>Genetic Epidemiology</i> , 2014 , 38, 467-76	2.6	10
157	Bulky DNA adduct formation and risk of bladder cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 2155-9	4	10
156	Prognostic value of stem cell quantification in stage II colon cancer. <i>PLoS ONE</i> , 2014 , 9, e88480	3.7	10
155	First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). <i>BMC Cancer</i> , 2019 , 19, 533	4.8	9
154	Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e287-e293	3.8	9
153	Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015 , 15, 579-89	2.2	9
152	BRAF Mutated Colorectal Cancer: New Treatment Approaches. <i>Cancers</i> , 2020 , 12,	6.6	9
151	Lifetime history of alcohol consumption and K-ras mutations in pancreatic ductal adenocarcinoma. <i>Environmental and Molecular Mutagenesis</i> , 2009 , 50, 421-30	3.2	9
150	Past medical conditions and K-ras mutations in pancreatic ductal adenocarcinoma: a hypothesis-generating study. <i>Cancer Causes and Control</i> , 2009 , 20, 591-9	2.8	9
149	Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. <i>Lung Cancer</i> , 2009 , 63, 83-7	5.9	9
148	Capecitabine plus oxaliplatin for the treatment of colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 161-74	3.5	9
147	Diagnosis and staging of pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017 , 19, 1205-1216	3.6	8
146	Optimization of Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1999-2007	6.1	8
145	Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8

144	Asthma status is associated with decreased risk of aggressive urothelial bladder cancer. <i>International Journal of Cancer</i> , 2018 , 142, 470-476	7.5	8
143	Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	8
142	Clinical behavior of solitary fibrous tumor: a retrospective review of 30 patients. <i>Clinical and Translational Oncology</i> , 2017 , 19, 357-363	3.6	8
141	Porocarcinoma: clinical evolution. <i>Dermatologic Surgery</i> , 2010 , 36, 264-7	1.7	8
140	Determinants of quality of interview and impact on risk estimates in a case-control study of bladder cancer. <i>American Journal of Epidemiology</i> , 2009 , 170, 237-43	3.8	8
139	Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3560-3560	2.2	8
138	A phase Ib study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) +/- paclitaxel protein bound particles (nab-paclitaxel) in pts with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4118-4118	2.2	8
137	A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 341-341	2.2	8
136	Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes. <i>Environment International</i> , 2020 , 135, 105346	12.9	8
135	Biomarkers in pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017 , 19, 1430-1433	3.6	7
134	Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2013 , 15, 705-11	3.6	7
133	Guidelines for the detection and treatment of liver metastases of colorectal cancer. <i>Clinical and Translational Oncology</i> , 2007 , 9, 723-30	3.6	7
132	Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2005 , 4, 384-9	3.8	7
131	Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. <i>Annals of Oncology</i> , 2003 , 14, 1549-54	10.3	7
130	Tumour location and efficacy of first-line EGFR inhibitors in wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials. <i>ESMO Open</i> , 2019 , 4, e000599	6	7
129	SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). <i>Clinical and Translational Oncology</i> , 2021 , 23, 988-1000	3.6	7
128	Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models. <i>BMC Cancer</i> , 2016 , 16, 351	4.8	7
127	Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1144-50	4	7

126	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 165-177	3.8	6
125	Surgery for pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017 , 19, 1303-1311	3.6	6
124	Follow-up recommendations and risk-reduction initiatives for Lynch syndrome. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1359-67	3.5	6
123	New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 457-67	3.5	6
122	Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor. <i>Anti-Cancer Drugs</i> , 2011 , 22, 477-9	2.4	6
121	Molecular biology of exocrine pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2006 , 8, 306-12	3.6	6
120	Compassionate use program with FDT-TPI (trifluridine-tipiracil) in pre-treated metastatic colorectal cancer patients: Spanish real world data.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15019-e15019	2.2	6
119	Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 553-8	7.3	6
118	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. <i>Genome Medicine</i> , 2021 , 13, 15	14.4	6
117	Management and supportive treatment of frail patients with metastatic pancreatic cancer. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 398-404	3.6	5
116	Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists. <i>Clinical and Translational Oncology</i> , 2014 , 16, 914-20	3.6	5
115	TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2014 , 16, 865-78	3.6	5
114	Real-world healthcare resource utilization in a European non-small cell lung cancer population: the EPICLIN-Lung study. <i>Current Medical Research and Opinion</i> , 2014 , 30, 463-70	2.5	5
113	Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). <i>Clinical and Translational Oncology</i> , 2010 , 12, 481-92	3.6	5
112	Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy). <i>Clinical and Translational Oncology</i> , 2006 , 8, 98-102	3.6	5
111	Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer. <i>Annals of Oncology</i> , 2004 , 15, 559-67	10.3	5
110	Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2003 , 25, 639-43		5
109	Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. <i>Gastroenterology</i> , 2021 ,	13.3	5

108	The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. <i>Oncologist</i> , 2020 , 25, e1-e4	5.7	5
107	A faecal microbiota signature with high specificity for pancreatic cancer.. <i>Gut</i> , 2022 ,	19.2	5
106	Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients. <i>Clinical and Translational Oncology</i> , 2009 , 11, 446-54	3.6	4
105	Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors. <i>Anti-Cancer Drugs</i> , 2004 , 15, 469-71	2.4	4
104	Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis.. <i>EBioMedicine</i> , 2021 , 75, 103797	8.8	4
103	Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998 , 21, 151-4	2.7	4
102	Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. <i>International Journal of Cancer</i> , 2019 , 144, 1540-1549	7.5	4
101	Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2021 , 148, 2048-2058	7.5	4
100	Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2019 , 20, 305-312.e3	4.9	3
99	Treatment patterns for metastatic colorectal cancer in Spain. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1455-1462	3.6	3
98	Management of hyperbilirubinaemia in pancreatic cancer patients. <i>European Journal of Cancer</i> , 2018 , 94, 26-36	7.5	3
97	Recommendations on current approach to gastric cancer. <i>Clinical and Translational Oncology</i> , 2009 , 11, 518-25	3.6	3
96	Elderly colorectal cancer patients are under treated. <i>European Journal of Cancer, Supplement</i> , 2004 , 2, 8-13	1.6	3
95	Regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy (PChT) patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2018 , 34, 3527-3527	2.2	3
94	Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients. <i>Molecular Cancer</i> , 2021 , 20, 73	42.1	3
93	Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. <i>Cancers</i> , 2021 , 13,	6.6	3
92	Detection of Early-Stage Pancreatic Ductal Adenocarcinoma from blood samples: Results of a multiplex biomarker signature validation study.. <i>Clinical and Translational Gastroenterology</i> , 2022 , 13,	4.2	3
91	Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. <i>Scientific Reports</i> , 2017 , 7, 41371	4.9	2

90	Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. <i>Journal of Pain Research</i> , 2019 , 12, 2349-2358	2.9	2
89	CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis. <i>Bladder Cancer</i> , 2019 , 5, 159-169	1	2
88	A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2019 , 121, 378-383	8.7	2
87	Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2011 , 22, 817-21	2.4	2
86	Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 75-82	3.5	2
85	Resolution of pleural effusion in a IgD multiple myeloma after chemotherapy based on liposomal doxorubicin. <i>Chinese-German Journal of Clinical Oncology</i> , 2007 , 6, 509-510		2
84	Panhypopituitarism as first manifestation of a lung cancer. <i>Clinical and Translational Oncology</i> , 2007 , 9, 53-5	3.6	2
83	Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis. <i>Clinical and Translational Oncology</i> , 2008 , 10, 241-5	3.6	2
82	P53 IN BLADDER CANCER PROGNOSIS. RESULTS FROM A PROSPECTIVE MULTICENTRIC STUDY IN SPAIN. <i>European Urology Supplements</i> , 2006 , 5, 805	0.9	2
81	Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial. <i>Clinical Colorectal Cancer</i> , 2001 , 1, 43-6	3.8	2
80	First-line biological agents plus chemotherapy in elderly patients with metastatic colorectal cancer: A retrospective pooled analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4017-4017	2.2	2
79	Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist. <i>Cancers</i> , 2021 , 13,	6.6	2
78	Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer 2000 , 2, 154-158		2
77	Survey of treatment recommendations for elderly patients with glioblastoma. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1329-1334	3.6	2
76	Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
75	Bratislava Statement: consensus recommendations for improving pancreatic cancer care. <i>ESMO Open</i> , 2020 , 5, e001051	6	2
74	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. <i>Oncologist</i> , 2020 , 25, e1428-e1432	5.7	2
73	Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. <i>Future Oncology</i> , 2021 , 17, 1843-1854	3.6	2

72	First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. <i>Drugs and Aging</i> , 2021 , 38, 219-231	4.7	2
71	Efficacy of adjuvant chemotherapy for elderly patients with colon cancer. <i>Annals of Oncology</i> , 2018 , 29, v65	10.3	2
70	Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Consortium. <i>Gastroenterology</i> , 2021 , 161, 1751-1757	13.3	2
69	Deposition-associated diseases related with a monoclonal compound. <i>Clinical and Translational Oncology</i> , 2007 , 9, 777-83	3.6	1
68	UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors. <i>Anti-Cancer Drugs</i> , 2006 , 17, 417-21	2.4	1
67	A phase III, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine (G) as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4135-TPS4135	2.2	1
66	Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3530-3530	2.2	1
65	Accomplishments in 2007 in the treatment of advanced colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, S19-24		1
64	Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). <i>European Journal of Surgical Oncology</i> , 2021 ,	3.6	1
63	Cisplatin and vinorelbine combination chemotherapy in inoperable non small cell lung cancer (NSCLC) : a multicenter phase II trial 2000 , 2, 84-90		1
62	Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS	2.2	1
61	Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS3618-TPS3618	2.2	1
60	The Quality Oncology Practice Initiative program: Experience in Spain.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 214-214	2.2	1
59	Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. <i>European Journal of Cancer</i> , 2020 , 139, 51-58	7.5	1
58	Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals Negativity and a Longer Overall Survival. <i>Cancers</i> , 2021 , 13,	6.6	1
57	Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. <i>Clinical and Translational Oncology</i> , 2021 , 1	3.6	1
56	Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Case-Control Studies.. <i>Environmental Health Perspectives</i> , 2022 , 130, 57006	8.4	1
55	Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers. <i>United European Gastroenterology Journal</i> , 2019 , 7, 682-688	5.3	0

54	Precision Medicine: Genotyping to Better Manage Irinotecan-Induced Toxicity.. <i>JCO Oncology Practice</i> , 2022 , OP2100858	2.3	o
53	Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation. <i>Oncotarget</i> , 2020 , 11, 2137-2140	3.3	o
52	The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211043341	3.2	o
51	Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 774170	5.6	o
50	Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments.. <i>European Journal of Cancer</i> , 2022 , 166, 229-239	7.5	o
49	European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish. <i>Clinical and Translational Oncology</i> , 2017 , 19, 288-290	3.6	
48	Screening of Individuals at High Risk for Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1916-1917	6.9	
47	Ramucirumab treatment in hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2020 , 9, 83	2.3	
46	Author's reply to: Air pollution and incident bladder cancer: A risk assessment. <i>International Journal of Cancer</i> , 2019 , 145, 3178	7.5	
45	Oncological translational research in the Spanish national health system: the INTRO study. <i>Clinical and Translational Oncology</i> , 2014 , 16, 686-95	3.6	
44	Journal Watch: Our expert panel highlights the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. <i>Colorectal Cancer</i> , 2013 , 2, 391-393	0.8	
43	Journal Watch: Our experts highlight the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. <i>Colorectal Cancer</i> , 2013 , 2, 109-111	0.8	
42	Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). <i>Clinical and Translational Oncology</i> , 2011 , 13, 411-8	3.6	
41	Evaluation of Spanish hospitals participating in the Quality Oncology Practice Initiative program.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 222-222	2.2	
40	Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant colon cancer: Experience in Ramon y Cajal University Hospital.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 815-815	2.2	
39	Prognostic relevance of primary tumor location in stage III and II colon cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 703-703	2.2	
38	Benefit of adjuvant treatment in stages II and III colon cancer: Experience at the Ramon y Cajal University Hospital.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 842-842	2.2	
37	Impact of adjuvant chemotherapy treatment according to tumor primary location in colorectal cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 655-655	2.2	

- 36 Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project.. *Journal of Clinical Oncology*, **2018**, 36, e22175-e22175 2.2
- 35 The future of precision medicine, strengths and weaknesses: An expert position paper.. *Journal of Clinical Oncology*, **2018**, 36, e18879-e18879 2.2
- 34 Safety of self-expandable metal stents (SEMS) or emergency surgery for acute malignant colonic obstruction in patients treated with bevacizumab.. *Journal of Clinical Oncology*, **2018**, 36, e15505-e15505^{2.2}
- 33 Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study.. *Journal of Clinical Oncology*, **2018**, 36, e18785-e18785 2.2
- 32 The Quality Oncology Practice Initiative program: Experience in Spain.. *Journal of Clinical Oncology*, **2018**, 36, 310-310 2.2
- 31 Strategies for reducing grade 2 and 3 adverse events due to immunotherapy in a Spanish university hospital.. *Journal of Clinical Oncology*, **2018**, 36, 288-288 2.2
- 30 Direct impact of clinical research in metastatic renal cell carcinoma (mRCC): A cost-effectiveness analysis of patient care outcomes and cost savings in a real-life scenario of a large public university hospital in Spain.. *Journal of Clinical Oncology*, **2019**, 37, 637-637 2.2
- 29 QIM19-125: Nonclinical Needs of Cancer Patients in Spain Under Different Perspectives: A Comparative Study. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, QIM19-125^{7.3}
- 28 Implementation of the Quality Training Program in Spain.. *Journal of Clinical Oncology*, **2019**, 37, e18296-e18296
- 27 Non-clinical needs of cancer patients in Spain under different perspectives: A comparative study.. *Journal of Clinical Oncology*, **2019**, 37, e18266-e18266 2.2
- 26 Nab-paclitaxel plus gemcitabine versus FOLFIRINOX in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: A national cohort (Comunica-TTD working group).. *Journal of Clinical Oncology*, **2019**, 37, e15707-e15707 2.2
- 25 The Quality Oncology Practice Initiative Program: Experience in Spain.. *Journal of Clinical Oncology*, **2019**, 37, e18267-e18267 2.2
- 24 Circulating endothelial cells: Prognostic value in patients with glioblastoma.. *Journal of Clinical Oncology*, **2019**, 37, e13517-e13517 2.2
- 23 Strategies for reducing grade 2 and 3 adverse events due to immunotherapy in a Spanish university hospital.. *Journal of Clinical Oncology*, **2019**, 37, e18295-e18295 2.2
- 22 Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).. *Journal of Clinical Oncology*, **2014**, 32, TPS3651-TPS3651 2.2
- 21 Proportional shortfall due to pancreatic cancer in Europe: Survival and quality of life analysis based on a systematic review.. *Journal of Clinical Oncology*, **2014**, 32, e15253-e15253 2.2
- 20 Survival surrogates in gastric cancer after first- and second-line chemotherapy treatment: A Spanish retrospective study from one institution.. *Journal of Clinical Oncology*, **2014**, 32, e15019-e15019 2.2
- 19 Prognostic factors in advanced gastric cancer after second-line treatment.. *Journal of Clinical Oncology*, **2015**, 33, 201-201 2.2

- 18 Genetic and phenotypic characterization of families with familial pancreatic cancer and screening of high-risk individuals.. *Journal of Clinical Oncology*, **2015**, 33, 242-242 2.2
- 17 Tumor markers as predictors of outcome in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy.. *Journal of Clinical Oncology*, **2015**, 33, e15061-e15061² 2.2
- 16 Comparison of three different molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer samples (mCRC): Interim analysis of a Spanish cohort.. *Journal of Clinical Oncology*, **2015**, 33, e14613-e14613 2.2
- 15 KRAS mutant circulating free DNA (cfDNA) and circulating tumor cell (CTC) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.. *Journal of Clinical Oncology*, **2015**, 33, e15252-e15252 2.2
- 14 Kaposi sarcoma: A retrospective review.. *Journal of Clinical Oncology*, **2015**, 33, e21520-e21520 2.2
- 13 Circulating biomarkers exploratory study in loco-regional gastroesophageal adenocarcinoma patients.. *Journal of Clinical Oncology*, **2016**, 34, 17-17 2.2
- 12 Comparison of three molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2016**, 34, 3559-3559 2.2
- 11 Identification of quality care indicators in prostate cancer.. *Journal of Clinical Oncology*, **2017**, 35, 213-213.2 2.2
- 10 Study on compliance with breakthrough cancer pain guidelines by medical oncologists in Spain.. *Journal of Clinical Oncology*, **2017**, 35, e18260-e18260 2.2
- 9 Chemotherapy-induced changes in the physiologic reserve of elderly patients diagnosed with cancer.. *Journal of Clinical Oncology*, **2012**, 30, e19590-e19590 2.2
- 8 Spanish national hereditary pancreatic cancer registry (PanFAM).. *Journal of Clinical Oncology*, **2012**, 30, e12033-e12033 2.2
- 7 Prognostic value of stem cell quantification in stage II colon cancer.. *Journal of Clinical Oncology*, **2012**, 30, e21104-e21104 2.2
- 6 Imaging techniques in pancreatic cancer screening: Preliminary results from the PanGen-FAM registry.. *Journal of Clinical Oncology*, **2013**, 31, 1529-1529 2.2
- 5 A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective. *ESMO Open*, **2020**, 5, e000850⁶ 2.2
- 4 Chemotherapy for Nonresectable Pancreatic Cancer **2021**, 530-537
- 3 A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. *Targeted Oncology*, **2018**, 13, 69-78 5
- 2 Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications. *JCO Oncology Practice*, **2021**, 17, e1162-e1169 2.3
- 1 Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. *European Journal of Cancer Prevention*, **2021**, 30, 423-430 2

